Skip to main content

Leadership

2015 News Releases

Keyword Search
 
2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | 2006
DateTitle  
12/22/15Emergent BioSolutions Announces Composition of Board of Directors of New Spin-Off Company Aptevo TherapeuticsDownload PDFPrinter Friendly Version
12/21/15Emergent BioSolutions to Participate in First Quarter 2016 Investor ConferencesDownload PDFPrinter Friendly Version
11/24/15FDA Approves Emergent BioSolutions' BioThrax for Post-Exposure ProphylaxisDownload PDFPrinter Friendly Version
11/05/15Emergent BioSolutions Reports Third Quarter and Nine Months 2015 Financial ResultsDownload PDFPrinter Friendly Version
10/22/15Emergent BioSolutions to Release Third Quarter 2015 Financial Results and Conduct a Conference Call on November 5, 2015Download PDFPrinter Friendly Version
08/13/15Emergent BioSolutions Receives $44 Million CDC Contract to Further Advance Vaccinia Immune Globulin Intravenous ProgramDownload PDFPrinter Friendly Version
08/06/15Emergent BioSolutions Announces Plan to Implement Tax-Free Spin-Off of Biosciences Business Into a Separate Publicly-Traded CompanyDownload PDFPrinter Friendly Version
08/06/15Emergent BioSolutions Reports Second Quarter and Six Months 2015 Financial Results and Reaffirms 2015 GuidanceDownload PDFPrinter Friendly Version
08/03/15Emergent BioSolutions Expands Biodefense Business Through Launch of a Military-Grade Auto-Injector Device for Chemical ThreatsDownload PDFPrinter Friendly Version
07/23/15Emergent BioSolutions to Release Second Quarter 2015 Financial Results and Conduct a Conference Call on August 6, 2015Download PDFPrinter Friendly Version
07/20/15Emergent BioSolutions Awarded $19.7 Million BARDA Contract to Develop and Manufacture Ebola Monoclonal AntibodiesDownload PDFPrinter Friendly Version
05/19/15Emergent BioSolutions Signs Long-Term Manufacturing Agreement With Prometic Life SciencesDownload PDFPrinter Friendly Version
05/14/15Emergent BioSolutions to Hold Annual Meeting of Stockholders Thursday May 21, 2015 at 9:00 AM Eastern; Webcast Will be AvailableDownload PDFPrinter Friendly Version
05/13/15Oxford University, GSK, and Emergent BioSolutions Announce Initiation of a Prime Boost Study of Ebola Vaccine CandidatesDownload PDFPrinter Friendly Version
05/07/15Emergent BioSolutions Reports First Quarter 2015 Financial ResultsDownload PDFPrinter Friendly Version
04/30/15Emergent BioSolutions Expands Commercial Product Portfolio With FDA Approval of IXINITY, a Recombinant Factor IX Treatment for Hemophilia BDownload PDFPrinter Friendly Version
04/29/15Emergent BioSolutions to Participate in May and June 2015 Investor ConferencesDownload PDFPrinter Friendly Version
04/22/15Emergent BioSolutions Completes Investigation and Resumes BioThrax Manufacturing Activities; Re-Affirms Previous Full-Year 2015 Financial OutlookDownload PDFPrinter Friendly Version
03/25/15Emergent BioSolutions Receives FDA Approval of Anthrasil, Its Anthrax Immune Globulin, for Use in the Treatment of Inhalational AnthraxDownload PDFPrinter Friendly Version
03/24/15Emergent BioSolutions Awarded $31 Million Contract for Advanced Development of NuThrax, a Next Generation Anthrax VaccineDownload PDFPrinter Friendly Version
03/16/15Emergent BioSolutions Signs Agreements With Oxford University, GlaxoSmithKline, and NIAID for the Production of an MVA Ebola Zaire Vaccine CandidateDownload PDFPrinter Friendly Version
03/09/15Emergent BioSolutions and MorphoSys Initiate Phase 1 Clinical Study to Evaluate the Novel Oncology Immunotherapeutic MOR209/ES414 for Prostate CancerDownload PDFPrinter Friendly Version
03/05/15Emergent BioSolutions Reports Fourth Quarter and Twelve Months 2014 Financial Results and Provides Update on 2015 OutlookDownload PDFPrinter Friendly Version
02/20/15Emergent BioSolutions to Participate in March 2015 Investor ConferencesDownload PDFPrinter Friendly Version
02/13/15Emergent BioSolutions Announces Primary Endpoints Met in Pivotal Study Supporting Licensure of Building 55Download PDFPrinter Friendly Version
02/12/15Emergent BioSolutions to Release Fourth Quarter and Full Year 2014 Financial Results and Conduct a Conference Call on March 5, 2015Download PDFPrinter Friendly Version
01/11/15Emergent BioSolutions Announces Preliminary 2014 Financial Results and Provides 2015 Financial OutlookDownload PDFPrinter Friendly Version
01/07/15Emergent BioSolutions to Participate in January 2015 Investor ConferencesDownload PDFPrinter Friendly Version